VIVEbiotech Highlights Progress and Challenges in In Vivo Gene Therapy at the Advanced Therapies Congress
Natalia Elizalde discusses key hurdles in translating in vivo gene therapies from promise to clinical reality in an IBTV interview
VIVEbiotech has been featured in Technology Networks through an interview conducted by IBTV with its Chief Business Officer, Natalia Elizalde, during the Advanced Therapies Congress held in the UK.
In the interview, Natalia explored the journey of in vivo gene therapy from scientific promise to real-world application, emphasizing key factors such as purity, cost-effectiveness, and the use of high-quality raw materials from early development stages. She also highlighted the importance of continuously optimizing production processes and advancing targeting strategies, including vector design and new pseudotypes.
Beyond these core elements, the discussion raises a crucial question: how can scientific potential be translated into tangible patient impact? One of the main challenges in in vivo gene therapy is achieving efficient and precise delivery of genetic material to target cells while minimizing off-target effects. To address this, the field is progressing through the development of tissue-specific promoters and next-generation delivery systems, enhancing both safety and therapeutic efficacy.
At the manufacturing level, ensuring batch-to-batch consistency and scalability remains essential. In this regard, VIVEbiotech is making progress with the launch of EvoLVcell, its stable producer cell line platform designed to reduce variability, enable scalable production, and lower cost of goods, supporting more predictable manufacturing strategies.
Looking ahead, technologies such as artificial intelligence and machine learning are set to transform the entire gene therapy lifecycle. Innovations like AI-driven process modeling and digital twins—virtual replicas of manufacturing processes—are already helping optimize performance and anticipate deviations.
Natalia also underscored the importance of early regulatory planning in a rapidly evolving landscape.
With expertise in both ex vivo and in vivo lentiviral vectors, along with advanced manufacturing platforms, VIVEbiotech continues to bridge the gap between scientific innovation and real patient impact.
Click here to watch the full interview.